Barclays PLC Humacyte, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Humacyte, Inc. stock. As of the latest transaction made, Barclays PLC holds 236,742 shares of HUMA stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

236,742

Previous 85,284 177.59%

Holding current value

$1.15 Million

Previous $409,000 214.91%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$5.11 - $9.46 $773,950 - $1.43 Million	151,458 Added 177.59%	236,742 $1.29 Million
Q2 2024 Aug 14, 2024	BUY	$2.87 - $9.1 $52,575 - $166,702	18,319 Added 27.36%	85,284 $409,000
Q1 2024 May 15, 2024	SELL	$2.57 - $4.84 $77,670 - $146,274	-30,222 Reduced 31.1%	66,965 $208,000
Q4 2023 Feb 15, 2024	BUY	$1.99 - $3.12 $146,064 - $229,004	73,399 Added 308.55%	97,187 $276,000
Q3 2023 Nov 07, 2023	SELL	$2.75 - $4.48 $129,401 - $210,806	-47,055 Reduced 66.42%	23,788 $70,000
Q2 2023 Aug 03, 2023	BUY	$2.86 - $4.97 $76,050 - $132,157	26,591 Added 60.09%	70,843 $203,000
Q1 2023 May 04, 2023	BUY	$2.11 - $3.25 $29,845 - $45,971	14,145 Added 46.98%	44,252 $136,000
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.62 $30,372 - $54,430	15,036 Added 99.77%	30,107 $63,000
Q3 2022 Nov 03, 2022	SELL	$1.22 - $5.14 $167 - $704	-137 Reduced 0.9%	15,071 $49,000
Q2 2022 Aug 12, 2022	BUY	$3.21 - $7.86 $2,076 - $5,085	647 Added 4.44%	15,208 $49,000
Q1 2022 May 16, 2022	BUY	$4.65 - $7.4 $67,708 - $107,751	14,561 New	14,561 $103,000

Others Institutions Holding HUMA

# of Institutions

150

Shares Held

35.1M

Call Options Held

279K

Put Options Held

607K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $499M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account